Personalized T-cell therapy achieves complete remission in therapy-resistant kidney tumor

A seventeen-year-old boy in Heidelberg had been fighting kidney cancer for a decade. He was seven when the tumor first appeared. Over the years, it came back again and again, spreading to his lungs, liver, pelvis, and brain. By the time he reached adolescence, the disease had become what doctors call far advanced—multiple large tumors in his abdomen, metastases scattered across several organs, and no standard treatment left to try. He had exhausted the usual options. No clinical trials would take him. The prognosis was grim.

Then his medical team at the Hopp Children's Cancer Center Heidelberg decided to attempt something different. They sent tumor samples for molecular analysis through a program called INFORM, which sequences cancer cells to find their vulnerabilities. The analysis revealed that his cancer cells were producing a protein called PRAME—a target that had shown promise in adult cancers like melanoma. The center's physicians, led by Christian Seitz, knew of recent clinical successes with PRAME-targeted therapies from a biotechnology company called Immatics, based in Tübingen. The data was compelling enough to justify trying a personalized approach, even in a patient with nothing left to lose.

The treatment itself was elegant in concept but complex in execution. Doctors extracted the boy's own T cells—immune cells that normally fight infection—and sent them to a laboratory at the National Center for Tumor Diseases in Heidelberg. There, a team led by Patrick Schmidt genetically modified these cells, reprogramming them to recognize and attack cancer cells bearing the PRAME protein. Immatics provided the genetic vector, the molecular instruction set that made this reprogramming possible. After seven days of manufacturing, the modified cells were ready. In July 2025, the boy received an infusion of his own engineered immune cells.

What happened next was striking. Nine days after the infusion, a tumor biopsy showed something remarkable: the modified T cells had infiltrated the tumor tissue in massive numbers, and cancer cells were dying. Over the following weeks and months, the tumors shrank across all affected organs. Three months after treatment, a second biopsy found no living cancer cells. Nearly a year later, imaging and blood tests showed no evidence of active disease. The boy was in excellent condition—training regularly, competing in cycling races, completing vocational training, and planning to pursue his Abitur, the German university entrance qualification.

The case was published in the New England Journal of Medicine, a signal of its significance to the medical world. But the team saw it as more than a single success story. Data from over 2,500 patients in the INFORM study showed that PRAME appears in many high-risk pediatric tumors, suggesting this approach could help other children. The Dietmar Hopp Foundation committed 1.8 million euros to fund a Phase I/II clinical trial called PRAMEtime, planned to begin in 2027. The trial will enroll up to eighteen children and adolescents aged eight to seventeen with PRAME-positive solid tumors. Immatics will continue providing the vector, while a newly established Center for Innovative Therapies in Heidelberg will manufacture the cells locally.

The breakthrough underscores something important about how new cancer treatments reach children. Pediatric cancer patient populations are small, which makes commercial development difficult. Academic medical centers often must lead the way, and they depend on private funding to do so. This case also illustrates the power of partnership—between a university hospital, a research institute, and a biotech company, each bringing expertise and resources. For one teenager, the collaboration meant a second chance at life. For others waiting in the pipeline, it offers the possibility of hope where none existed before.